VECIMA/VECTOR/LIBERTY
17.5.2021 14:02:57 CEST | Business Wire | Press release
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint.
The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency.
“The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generation broadband networks in Europe,” said Seamus Gallagher, Liberty Global’s VP of Access Network Strategy. “Currently, we have over 19 million homes connected throughout Europe with speeds of 1Gbps. DAA brings many benefits, such as increased network bandwidth and less equipment in the headend and hub by enabling a multi-service - video/data/voice/mobile backhaul - unified, fiber core network. We are excited to continue our gigabit rollout with a solution that helps avoid vendor lock-in and supports multi-vendor interoperability.”
Liberty Global, with support from Vecima and Vector Technologies, plans to complete field trials in Autumn 2021 in their Western and Central Europe operating companies. The trials showcase R-PHY’s operational efficiency and the planned deployment cement Liberty Global as a worldwide leader in next-gen gigabit broadband.
‟We are excited to partner with both Liberty Global and Vector Technologies to leverage our Entra DAA solutions to transform consumer experiences in homes, businesses, and anywhere that people connect,” said Clay McCreery, Chief Operating Officer at Vecima. “Utilizing existing network infrastructures, Vecima is committed to building and delivering the industry’s most innovative cable access solutions that will deliver ground-breaking speed and capacity. Liberty is one of the leading operators in the world, and we’re proud to help enable their strategic vision.”
Liberty Global requirements included a solution that was fully interoperable with their deployed CCAP Core platforms. The Vecima ERM112 RPD module gives Liberty Global the freedom to source access network elements from multiple vendors, enhancing cost efficiency and accelerating time to market. Vector Technologies acted as the integrator for the project and performed all necessary tests at its DAA and DOCSIS laboratories.
"Vector Technologies and Vecima built a solution that supports a standards-based, multi-vendor environment. We believe that openness is the key to building the access network of the future, and we are committed to building scalable, secure, and simple solutions to manage network solutions that avoid vendor lock-in scenarios," said Maciej Muzalewski, CTO of Vector Technologies. “ We performed all the essential tests at our high-tech laboratories, which we built to support future DOCSIS and DAA implementations. We are delighted to continue our partnership with Liberty Global as an integrator, helping them forge ahead to gigabit speeds across their footprint."
Bridging the new 10G digital fiber CIN networks and the legacy RF coax plant, the combined Vector Technologies and Vecima solution supports architectures that push fiber deeper into the network, allowing operators to leverage existing network capacity and deliver increased bandwidth to subscribers.
About Liberty Global
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in seven European countries under the consumer brands Virgin Media, Telenet, UPC, the combined Sunrise UPC, as well as VodafoneZiggo, which is owned through a 50/50 joint venture. Our substantial scale and commitment to innovation enable us to invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.
Liberty Global delivers market-leading products through next-generation networks that connect customers subscribing to 50 million broadband, video, fixed and mobile telephony services across our brands. We also have significant investments in ITV, All3Media, ITI Neovision, LionsGate, the Formula E racing series and several regional sports networks.
For more information, please visit www.libertyglobal.com
.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery, and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high‑capacity broadband network access, and streamline data analytics.
Further information about Vecima’s Entra solution is available at https://vecima.com/solutions/distributed-access/
. Or visit our website at www.vecima.com
.
About Vector Technologies
Vector Technologies acts as a European competence center for the world’s largest Multiple System Operators and support them in network transformation towards Distributed Access Architecture.
As an experienced partner, we:
- integrate, optimize and design solutions for Next Generation Access Networks
- define the best directions of technological development in the area of Distributed Access Architecture (DAA) or Passive Optical Networks (PON) and Software-Defined Networking (SDN)
- support Multiple System Operators in the efficient technology migrations
- help operators in increasing efficiency and availability of provided services
- have proven field experience in managing turnkey projects for Remote-PHY, DAA, DOCSIS 3.1 and DOCSIS 3.0
For more information, updates and useful links, please visit our website: https://vectortechnologies.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom